Shanghai Fosun Pharmaceutical Industrial Development Company Limited cancelled the acquisition of 28% stake in Guangzhou Dihuixin Medical Devices Co., Ltd from Hangzhou Digui Holdings Co., Ltd and Dian Diagnostics Group Co., Ltd..
June 20, 2019
Share
Shanghai Fosun Pharmaceutical Industrial Development Company Limited signed an equity transfer agreement to acquire 28% stake in Guangzhou Dihuixin Medical Devices Co., Ltd from Hangzhou Digui Holdings Co., Ltd and Dian Diagnostics Group Co., Ltd. (SZSE:300244) for approximately CNY 410 million on June 20, 2018. The consideration is paid in cash. Under the terms, the consideration will be done within 10 days since signing of the agreement in one single installment. Hangzhou Digui Holdings Co., Ltd holds 64% stake in the Guangzhou Dihuixin Medical Devices Co., Ltd. Guangzhou Dihuixin Medical Devices Co., Ltd reported total assets of CNY 861.1 million, net assets of CNY 600.6 million, operational income of CNY 1.03 billion and net profit of CNY 170.4 million as of December 31, 2017. The transaction doesn’t need approval from the shareholders at the meeting.
Shanghai Fosun Pharmaceutical Industrial Development Company Limited cancelled the acquisition of 28% stake in Guangzhou Dihuixin Medical Devices Co., Ltd from Hangzhou Digui Holdings Co., Ltd and Dian Diagnostics Group Co., Ltd. (SZSE:300244) on June 20, 2019.
Dean Diagnostic Technology Group Co., Ltd. is a company providing integrated solutions for medical diagnosis. The Company's main business involves inspection services, product services, health management, judicial expertise, contract research organization (CRO), cold chain logistics and other fields. The Company's business is mainly oriented to medical and health institutions at all levels, such as various general and specialized hospitals, community health service centers, township (town) health centers, physical examination centers, disease prevention and control centers, etc. The Company's products include Atomic Bomb in the field of liquid phase mass spectrometry, Hydrogen Bomb in the field of nucleic acid mass spectrometry, and Man-Made Satellite in the field of pathological diagnosis products and molecular diagnosis products, and others.
Shanghai Fosun Pharmaceutical Industrial Development Company Limited cancelled the acquisition of 28% stake in Guangzhou Dihuixin Medical Devices Co., Ltd from Hangzhou Digui Holdings Co., Ltd and Dian Diagnostics Group Co., Ltd..